A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Status:
Completed
Trial end date:
2019-04-15
Target enrollment:
Participant gender:
Summary
This randomized Phase III study is to evaluate whether pazopanib compared with placebo can
prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of
developing recurrence after undergoing kidney cancer surgery.